Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MARS1 | P56192 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28626435 | 0.87 | KDM4E (0.34) | RIPK1HTTPOLBKDM4E | |
| SCHEMBL28626441 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL23652755 | 0.79 | KDM4E (0.34) | ALDH1A1POLBKDM4E | |
| SCHEMBL23645451 | 0.79 | KMO (0.32) | RIPK1 | |
| SCHEMBL23652648 | 0.79 | KMO (0.32) | — | |
| SCHEMBL23652816 | 0.78 | DAO (0.33) | — | |
| SCHEMBL23652650 | 0.77 | POLB (0.31) | POLB | |
| SCHEMBL23645426 | 0.77 | KDM4E (0.35) | ALDH1A1POLBKDM4E | |
| SCHEMBL23653011 | 0.77 | KDM4E (0.33) | POLBKDM4E | |
| SCHEMBL23645330 | 0.76 | KMO (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1988093-A1 | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | Wyeth a Corporation of the State of Delaware (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1885357-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006130588-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS | WYETH (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1499621-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| WO-2003093279-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | RIPK1 3999/4885TP53 2992/4885MEN1 838/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | RIPK1 4117/4885TP53 4377/4885MEN1 3520/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | RIPK1 4384/4885TP53 4211/4885MEN1 2819/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | RIPK1 4336/4885TP53 4309/4885MEN1 2190/4885 |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, PEPD, B2M | RIPK1 4386/4885TP53 4187/4885MEN1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.